Evidence for more intensive cholesterol lowering

Purpose of review In randomized clinical trials, reduction in cardiovascular disease (CVD) risk with cholesterol-lowering drugs correlates with the LDL cholesterol decrease. However, because the majority have investigated a fixed statin dose, current guidelines disagree about the use of statin dose titration or non-statin adjunctive cholesterol-lowering drugs. Recent findings We conducted a meta-analysis of all randomized controlled trials with CVD end-points, comparing two intensities of lipid-lowering regimens within the same population, using varying statins doses and/or potency, ezetimibe or PCSK9 inhibitors and compared the observed number of patients needed to be treated for 10 years to prevent one CVD event (NNT) with NNT predicted from trials of predominantly single-dose statin. Some 75439 participants in 10 randomized studies were included. The mean 10-year CVD risk in controls was around 50% and the incremental mean LDL cholesterol decrease 0.95 mmol/l (36.7 mg/dl). Observed NNT closely correlated with those predicted from predominantly single-dose statin trials [18.2 and 17.1; Pearson R=0.844 (P=0.001)]. When pre-treatment LDL cholesterol exceeded 4 mmol/l (155 mg/dl), achieving a target LDL cholesterol of 1.8 mmol/l (70 mg/dl) was the most effective strategy. At lower pre-treatment levels, fixed-dose statin equivalent to atorvastatin 80 mg daily was superior. The target of 40% reduction in non-high density lipoprotein cholesterol was least effective regardless of pre-treatment LDL cholesterol. Summary We conclude that when initial LDL cholesterol exceeds 4 mmol/l and absolute CVD risk demands it, a target value of 1.8 mmol/l should be achieved, if necessary by adding ezetimibe and/or PCSK9 inhibitors to statin treatment.

[1]  H. Soran,et al.  Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients. , 2017, Circulation.

[2]  Jennifer G. Robinson,et al.  Potential for Net Benefit Should Guide Preventive Therapy. , 2017, Circulation.

[3]  Jennifer G. Robinson,et al.  Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. , 2017, Journal of the American College of Cardiology.

[4]  H. Soran,et al.  Evidence-based goals in LDL-C reduction , 2017, Clinical Research in Cardiology.

[5]  H. Soran,et al.  Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat , 2017, European journal of preventive cardiology.

[6]  R. Hegele,et al.  Seeking ‘meta guidelines’ for lipids , 2017, European journal of preventive cardiology.

[7]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[8]  S. Mora,et al.  Re-assessing the role of non-fasting lipids; a change in perspective. , 2016, Annals of translational medicine.

[9]  Brian A Ference,et al.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[10]  Jennifer G. Robinson Lower might be better - It matters how you get there, and in whom. , 2016, European heart journal.

[11]  M. Pencina,et al.  Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease , 2016, Circulation.

[12]  J. Kostis,et al.  Role of Niacin in Current Clinical Practice: A Systematic Review. , 2016, The American journal of medicine.

[13]  Jennifer G. Robinson,et al.  Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Soran,et al.  Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. , 2015, European heart journal.

[15]  J. Mckenney,et al.  National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.

[16]  Ming Liu,et al.  Fibrates for secondary prevention of cardiovascular disease and stroke. , 2015, The Cochrane database of systematic reviews.

[17]  Y. Morino,et al.  Cellular and molecular mechanisms of statins: an update on pleiotropic effects. , 2015, Clinical science.

[18]  Improve-It Investigators Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[19]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[20]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[21]  Christos G Mihos,et al.  Cardiovascular effects of statins, beyond lipid-lowering properties. , 2014, Pharmacological research.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[23]  Shah Ebrahim,et al.  Statins for the primary prevention of cardiovascular disease (Review) , 2011 .

[24]  S. Adams,et al.  Lipid lowering efficacy of atorvastatin. , 2012, The Cochrane database of systematic reviews.

[25]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[26]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[27]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.

[28]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[29]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[30]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[31]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[32]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[33]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[34]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[35]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[36]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[37]  D. Chambers,et al.  Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal , 2016, PharmacoEconomics.

[38]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[39]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.